UNCY (Unicycive Therapeutics) Interest Expense: $-0.06 Mil (TTM As of Mar. 2026)


UNCY Unicycive Therapeutics Inc UNCY
32 GF Score
Price $5.44
! 2 Warning Signs
View Full Analysis

What is Unicycive Therapeutics Interest Expense?

Unicycive Therapeutics UNCY 32 Interest Expense is $-0.06 Mil as of Mar. 2026. GuruFocus rates UNCY with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Unicycive Therapeutics's interest expense for the three months ended in Mar. 2026 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.06 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Unicycive Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -8.44 Mil. Unicycive Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ 0.00 Mil. GuruFocus does not calculate Unicycive Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Unicycive Therapeutics  (NAS:UNCY) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Unicycive Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-8.44 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.22 Mil.

Unicycive Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Unicycive Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Unicycive Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Unicycive Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unicycive Therapeutics Interest Expense Chart

Unicycive Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.63 -0.01 -0.08 -0.07 -0.07

Unicycive Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.01 -0.02 -0.03 0.00
UNCY
32GF Score
Unicycive Therapeutics Inc UNCY
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unicycive Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.06 Mil mean?
Unicycive Therapeutics (UNCY) has a Interest Expense of $-0.06 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Unicycive Therapeutics and its competitors.
Is Unicycive Therapeutics' Interest Expense too high?
Unicycive Therapeutics' current Interest Expense is $-0.06 Mil. Overall, Unicycive Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Unicycive Therapeutics' Interest Expense compare to MDWD and ARCT?
Unicycive Therapeutics' Interest Expense of $-0.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Unicycive Therapeutics and its competitors. Unicycive Therapeutics's current Interest Expense is $-0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unicycive Therapeutics stock overvalued right now?
Unicycive Therapeutics (UNCY) has a current Interest Expense of $-0.06 Mil. The current Interest Expense is $-0.06 Mil. Unicycive Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Unicycive Therapeutics (UNCY), the current Interest Expense is $-0.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unicycive Therapeutics Business Description

Address 1975 W. El Camino Real, Suite 204, Mountain View, CA, USA, 94040
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
32GF Score

Get the complete analysis for UNCY

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.44
Price